ML19331B267
| ML19331B267 | |
| Person / Time | |
|---|---|
| Site: | Midland |
| Issue date: | 06/10/1970 |
| From: | Beck C US ATOMIC ENERGY COMMISSION (AEC) |
| To: | David Lindsay FOOD & DRUG ADMINISTRATION |
| Shared Package | |
| ML19331B268 | List: |
| References | |
| NUDOCS 8007280863 | |
| Download: ML19331B267 (1) | |
Text
.
s 1 Ly THIS DOCUMENT CONTAINS p uo P00R QUAUTY PAGES bec: CKBeck, DR JUN 101970 E Mann, DR HKShapar, OGC LRogers, RPS Dr. Dale R. Lindsay RCDeYoung, DRL Associate e===f asioner DRMuller, DRL for Science JAMurphy, DRL Food med Drug Administration DSSmith, RPS Room 1457, Parklawn Building JPVeerling, DML 5600 Fishers Lane LJohnson, DML Rockville, Maryland 20852 St. Br. Dist.
DML
Dear Dr. Lindsay:
DR PAMorris, DRL This refers to our meeting of May 19, 1970, in which we exchanged views about regulatory controls appropriate for steam which is to be produced by the Consumers Power Company nuclear reactor and used by the Dow Chemical Company at their IIidimut Division for manufacturing processes.
The enclosed letter from Dow establishes their intention to limit tas use of Constaters steam for thermal and mechanical energy c,nly. Dow has now indicated that they will isolate the steam from any intentional direct. con-tact with their products or their precursors. A copy of our reply to Dow is also enclosed.
We believe that the concept for use of the steam supplied by Consumers to Dow is one which is satisfactory from an AEC regulatory standpoint. We are prepared to receiva and evaluate an application for a 10 CPR Part 30 license for the use of secondary steam as Dow proposes. It is recognized that, in an operation as complex as Dow's, steam leaks from the secondary system to pro-ducts are likely to develop. Dow must establish a program for detection and repair of leaks so that radioactivity in products renains in the range of background. We will evaluate the proposals Dow submits for accomplishing these objectives and, of course, will not issue a license before we believe they are satisfactory.
We would be pleased to have your comments rogarding the compatibility of our proposed action with such functions as the FDA performs with respct to this proj ect.
Sincerely, 0"W Nm u t g Clifford K. Beck Deputy Director of Regulation ogosuN::
R
~
ADR ADR
- 1. LtE"3/28770"Dow to Aff""" ~ ~
" " ' " " " ' -"TM P C6HHlsg"y to b r
M ann
@ d SURP sE fsisidhs".."6L=]10R51iusBh[ONCURRENCESr 6fQO~ ~ ~
C
.L 6L QO 6f p o Q. QO
,,m oc.
u, f9f70, Ont>
6
--,.~ _
i 8007280 h f3
//
f
..